Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology

L. Pácal, K. Chalásová, A. Pleskačová, J. Řehořová, J. Tomandl, K. Kaňková,

. 2018 ; 19 (5) : . [pub] 20180518

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033065

Methylglyoxal production is increased in diabetes. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and CKD milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). A total of 83 subjects were included in the study. Gene expression was measured using real-time PCR, and protein levels were quantified using Western blotting. Erythrocyte GLO1 activity was measured spectrophotometrically. GLO1 gene expression was significantly higher in subjects with CKD1-2 compared to CKD3-4. GLO1 protein level was lower in diabetics than in non-diabetics. GLO1 activity in RBCs differed between the four groups being significantly higher in diabetics with CKD1-2 vs. healthy subjects and vs. nondiabeticsfig with CKD3-4. GLO1 activity was significantly higher in diabetics compared to nondiabetics. In conclusion, both diabetes and CKD affects the glyoxalase system. It appears that CKD in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. CKD decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033065
003      
CZ-PrNML
005      
20191002081757.0
007      
ta
008      
181008s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms19051517 $2 doi
035    __
$a (PubMed)29783710
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pácal, Lukáš $u Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. paci@med.muni.cz.
245    10
$a Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology / $c L. Pácal, K. Chalásová, A. Pleskačová, J. Řehořová, J. Tomandl, K. Kaňková,
520    9_
$a Methylglyoxal production is increased in diabetes. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and CKD milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). A total of 83 subjects were included in the study. Gene expression was measured using real-time PCR, and protein levels were quantified using Western blotting. Erythrocyte GLO1 activity was measured spectrophotometrically. GLO1 gene expression was significantly higher in subjects with CKD1-2 compared to CKD3-4. GLO1 protein level was lower in diabetics than in non-diabetics. GLO1 activity in RBCs differed between the four groups being significantly higher in diabetics with CKD1-2 vs. healthy subjects and vs. nondiabeticsfig with CKD3-4. GLO1 activity was significantly higher in diabetics compared to nondiabetics. In conclusion, both diabetes and CKD affects the glyoxalase system. It appears that CKD in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. CKD decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a diabetes mellitus $x krev $x patologie $7 D003920
650    _2
$a diabetické nefropatie $x krev $x patologie $7 D003928
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a laktoylglutathionlyasa $x krev $7 D007791
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyruvaldehyd $x krev $7 D011765
650    _2
$a chronická renální insuficience $x krev $x patologie $7 D051436
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chalásová, Katarína, $d 1986- $7 mub2017949800 $u Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. katarina.kuricova@gmail.com.
700    1_
$a Pleskačová, Anna $u Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. pleskacova@med.muni.cz. Department of Biochemistry, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. pleskacova@med.muni.cz.
700    1_
$a Řehořová, Jitka $u Department of Gastroenterology, University Hospital Brno, Jihlavská 20, 625 00 Brno, Czech Republic. rehorova.jitka@fnbrno.cz.
700    1_
$a Tomandl, Josef $u Department of Biochemistry, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. tomandl@med.muni.cz.
700    1_
$a Kaňková, Kateřina $u Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno, Czech Republic. kankov@med.muni.cz. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. kankov@med.muni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 19, č. 5 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29783710 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20191002082205 $b ABA008
999    __
$a ok $b bmc $g 1340787 $s 1030059
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 5 $e 20180518 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20181008
Back

Find record

Citation metrics

Archiving options